Cargando…

Future Directions in Diagnosis, Prognosis and Disease Monitoring of Adrenocortical Carcinoma: Novel Non-Invasive Biomarkers

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with frequent metastatic spread and poor prognosis. The disease can occur at any age with unexpected biological behavior. Recent genome-wide studies of ACC have contributed to our understanding of the disease, but diagnosis of ACC remains...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yuling, Kou, Wei, Zhu, Dandan, Yu, Xinbo, Zhu, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844185/
https://www.ncbi.nlm.nih.gov/pubmed/35178030
http://dx.doi.org/10.3389/fendo.2021.811293
_version_ 1784651425399177216
author Cheng, Yuling
Kou, Wei
Zhu, Dandan
Yu, Xinbo
Zhu, Yu
author_facet Cheng, Yuling
Kou, Wei
Zhu, Dandan
Yu, Xinbo
Zhu, Yu
author_sort Cheng, Yuling
collection PubMed
description Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with frequent metastatic spread and poor prognosis. The disease can occur at any age with unexpected biological behavior. Recent genome-wide studies of ACC have contributed to our understanding of the disease, but diagnosis of ACC remains a challenge, even for multidisciplinary expert teams. Patients with ACC are frequently diagnosed in advanced stages and have limited therapeutic options. Therefore, for earlier diagnosis and better clinical management of adrenocortical carcinoma, specific, sensitive, and minimal invasive markers are urgently needed. Over several decades, great efforts have been made in discovering novel and reliable diagnostic and prognostic biomarkers including microRNAs, steroid profilings, circulating tumor cells, circulating tumor DNAs and radiomics. In this review, we will summarize these novel noninvasive biomarkers and analyze their values for diagnosis, predicting prognosis, and disease monitoring. Current problems and possible future application of these non-invasive biomarkers will also be discussed.
format Online
Article
Text
id pubmed-8844185
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88441852022-02-16 Future Directions in Diagnosis, Prognosis and Disease Monitoring of Adrenocortical Carcinoma: Novel Non-Invasive Biomarkers Cheng, Yuling Kou, Wei Zhu, Dandan Yu, Xinbo Zhu, Yu Front Endocrinol (Lausanne) Endocrinology Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with frequent metastatic spread and poor prognosis. The disease can occur at any age with unexpected biological behavior. Recent genome-wide studies of ACC have contributed to our understanding of the disease, but diagnosis of ACC remains a challenge, even for multidisciplinary expert teams. Patients with ACC are frequently diagnosed in advanced stages and have limited therapeutic options. Therefore, for earlier diagnosis and better clinical management of adrenocortical carcinoma, specific, sensitive, and minimal invasive markers are urgently needed. Over several decades, great efforts have been made in discovering novel and reliable diagnostic and prognostic biomarkers including microRNAs, steroid profilings, circulating tumor cells, circulating tumor DNAs and radiomics. In this review, we will summarize these novel noninvasive biomarkers and analyze their values for diagnosis, predicting prognosis, and disease monitoring. Current problems and possible future application of these non-invasive biomarkers will also be discussed. Frontiers Media S.A. 2022-02-01 /pmc/articles/PMC8844185/ /pubmed/35178030 http://dx.doi.org/10.3389/fendo.2021.811293 Text en Copyright © 2022 Cheng, Kou, Zhu, Yu and Zhu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Cheng, Yuling
Kou, Wei
Zhu, Dandan
Yu, Xinbo
Zhu, Yu
Future Directions in Diagnosis, Prognosis and Disease Monitoring of Adrenocortical Carcinoma: Novel Non-Invasive Biomarkers
title Future Directions in Diagnosis, Prognosis and Disease Monitoring of Adrenocortical Carcinoma: Novel Non-Invasive Biomarkers
title_full Future Directions in Diagnosis, Prognosis and Disease Monitoring of Adrenocortical Carcinoma: Novel Non-Invasive Biomarkers
title_fullStr Future Directions in Diagnosis, Prognosis and Disease Monitoring of Adrenocortical Carcinoma: Novel Non-Invasive Biomarkers
title_full_unstemmed Future Directions in Diagnosis, Prognosis and Disease Monitoring of Adrenocortical Carcinoma: Novel Non-Invasive Biomarkers
title_short Future Directions in Diagnosis, Prognosis and Disease Monitoring of Adrenocortical Carcinoma: Novel Non-Invasive Biomarkers
title_sort future directions in diagnosis, prognosis and disease monitoring of adrenocortical carcinoma: novel non-invasive biomarkers
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844185/
https://www.ncbi.nlm.nih.gov/pubmed/35178030
http://dx.doi.org/10.3389/fendo.2021.811293
work_keys_str_mv AT chengyuling futuredirectionsindiagnosisprognosisanddiseasemonitoringofadrenocorticalcarcinomanovelnoninvasivebiomarkers
AT kouwei futuredirectionsindiagnosisprognosisanddiseasemonitoringofadrenocorticalcarcinomanovelnoninvasivebiomarkers
AT zhudandan futuredirectionsindiagnosisprognosisanddiseasemonitoringofadrenocorticalcarcinomanovelnoninvasivebiomarkers
AT yuxinbo futuredirectionsindiagnosisprognosisanddiseasemonitoringofadrenocorticalcarcinomanovelnoninvasivebiomarkers
AT zhuyu futuredirectionsindiagnosisprognosisanddiseasemonitoringofadrenocorticalcarcinomanovelnoninvasivebiomarkers